An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving landscape of Alzheimer's treatments.

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

It wasn’t long ago when a diagnosis of Alzheimer’s disease was not too far from a death sentence. While treatments have ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.